Rilpivirine (TMC278), is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.
[1] Namasivayam V, et al. J Med Chem. 2019 May 23;62(10):4851-4883.
















